The dual face of parathyroid hormone and prostaglandins in the osteoimmune system

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 10, 2013, Pages

  Agas, Dimitrios ^a   Marchetti, Luigi ^a   Capitani, Melania ^a   Sabbieti, Maria Giovanna ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Bone; Immune system; Osteoimmunology; Parathyroid hormone; Prostaglandins

Indexed keywords

ALPHA INTERFERON; ARACHIDONIC ACID; BETA INTERFERON; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; PARATHYROID HORMONE; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW; CLINICAL PROTOCOL; CYTOKINE PRODUCTION; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOIMMUNOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

BONE; IMMUNE SYSTEM; OSTEOIMMUNOLOGY; PARATHYROID HORMONE; PROSTAGLANDINS;

ANIMALS; BONE AND BONES; BONE MARROW; HUMANS; IMMUNE SYSTEM; PARATHYROID HORMONE; PROSTAGLANDINS; STEM CELL NICHE; T-LYMPHOCYTES;

EID: 84887570460     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00290.2013     Document Type: Review

References (152)

1. Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439: 599-603, 2006.
2. Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi LM, Kronenberg HM, Scadden DT. Therapeutic targeting of a stem cell niche. Nat Biotechnol 25: 238-243, 2007.
3. Agas D, Marchetti L, Menghi G, Materazzi S, Materazzi G, Capac-chietti M, Hurley MM, Sabbieti MG. Anti-apoptotic Bcl-2 enhancing requires FGF-2/FGF receptor 1 binding in mouse osteoblasts. J Cell Physiol 241: 145-152, 2008.
4. Agas D, Marchetti L, Hurley MM, Sabbieti MG. Prostaglandin F2a: a bone remodeling mediator. J Cell Physiol 228: 25-29, 2013.
5. Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, Bonewald LF. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 144: 1761-1769, 2003.
6. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20: 2254-2272, 2001.
7. Arai F, Hirao A, Omura M, Sato H, Matsuoka S, Takubo K. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118: 149-161, 2004.
8. Arron JR, Choi Y. Bone versus immune system. Nature 408: 535-536, 2000.
9. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 7: 370-375, 2008.
10. Basu S, Whiteman M, Mattey DL, Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2a) in different rheumatic diseases. Ann Rheum Dis 60: 627-631, 2001.
11. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lympho-kines but not of Th2 lymphokines. J Immunol 146: 108-113, 1991.
12. Bodine PV, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, Mangine A, Scrimo MJ, Bhat RA, Stauffer B, Green J, Stein GS, Lian JB, Komm BS. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 96: 1212-1230, 2005.
13. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7: 33-39, 2006.
14. Bonewald LF. The amazing osteocyte. J Bone Miner Res 26: 229-238, 2011.
15. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel M, Shido K, White IA, Kobayashi M, Witte L, May C, Shawber C, Kimura Y, Kitajewski J, Rosenwaks Z, Bernstein ID, Rafii S. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6: 251-264, 2010.
16. Caetano-Lopes J, Nery AM, Henriques R, Canhão H, Duarte J, Amaral PM, Vale M, Moura RA, Pereira PA, Weinmann P, Abdul-ghani S, Souto-Carneiro M, Rego P, Monteiro J, Sakagushi S, Queiroz MV, Konttinen YT, Graça L, Vaz MF, Fonseca JE. Chronic arthritis directly induces quantitative and qualitative bone disturbances leading to compromised biomechanical properties. Clin Exp Rheumatol 27: 475-482, 2009.
17. Calvi LM, Adams GB, Weibrecht W, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-846, 2003.
18. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357: 905-916, 2007.
19. Carpio L, Gladu J, Goltzman D, Rabbani SA. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281: E489-E499, 2001.
20. Chan GK, Miao D, Deckelbaum R, Bolivar I, Karaplis A, Goltzman D. Parathyroid hormone-related peptide interacts with bone morphoge-netic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology 144: 5511-5520, 2003.
21. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the athophysiology of osteoporosis. Immunol Rev 208: 207-227, 2005.
22. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 93: 1095-1101, 1994.
23. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol 61: 577-587, 2008.
24. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, Yoon K, Cook JM, Willert K, Gaiano N, Reya T. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6: 314-322, 2005.
25. Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 85: 1417-1423, 2013.
26. Fleming HE, Janzen V, Guo J, Celso CL, Leahy KM, Kronenberg HM, Scadden DT. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2: 274-283, 2008.
27. Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhão H, Resende C, Castelão W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M. Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 23: 185-192, 2005.
28. Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, Calvi LM. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood 114: 4054-4063, 2009.
29. Fujino H, West KA, Regan JW. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 277: 2614-2619, 2002.
30. Gao Y, Wu X, Terauchi M, Li JY, Grassi F, Galley S, Yang X, Weitzmann MN, Pacifici R. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab 8: 132-145, 2008.
31. Gentile P, Byer D, Pelus LM. In vivo modulation of murine myelopoi-esis following intravenous administration of prostaglandin E2. Blood 62: 1100-1107, 1983.
32. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5: 698-701, 1999.
33. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT, Zon LI. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136: 1136-1147, 2009.
34. Goessling W, Allen RS, Guan X, Jin P, Uchida N, Dovey M, Harris JM, Metzger ME, Bonifacino AC, Stroncek D, Stegner J, Armant M, Schlaeger T, Tisdale JF, Zon LI, Donahue RE, North TE. Prostaglan-din E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8: 445-458, 2011.
35. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473: 218-224, 2008.
36. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromalosteoblast lineage cells is developmen-tally regulated. Endocrinology 141: 4768-4777, 2000.
37. Hata AN, Breyer RM. Pharmacology and signalling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147-166, 2004.
38. Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 14: 245-253, 2008.
39. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 5212-5220, 2003.
40. Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 113: 5444-5555, 2009.
41. Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203: 325-335, 2006.
42. Hooper AT, Butler J, Petit I, Rafii S. Does N-cadherin regulate interaction of hematopoietic stem cells with their niches? Cell Stem Cell 1: 127-129, 2007.
43. Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, Lindsay R. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186: 549-557, 2005.
44. Ikushima YM, Arai F, Hosokawa K, Toyama H, Takubo K, Fu-ruyashiki T, Narumiya S, Suda T. Prostaglandin E2 regulates murine hematopoietic stem/progenitor cells directly via EP4 receptor and indirectly through mesenchymal progenitor cells. Blood 121: 1995-2007, 2013.
45. Ikushima YM, Arai F, Nakamura Y, Hosokawa K, Kubota Y, Hirashima M, Toyama H, Suda T. Enhanced Angpt1/Tie2 signaling affects the differentiation and long-term repopulation ability of hematopoietic stem cells. Biochem Biophys Res Commun 430: 20-25, 2013.
46. Isogai Y, Akatsu T, Ishizuya T, Yamaguchi A, Hori M, Takahashi N, Suda T. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res 11: 1384-1393, 1996.
47. Jiang Y, Bonig H, Ulyanova T, Chang K, Papayannopoulou T. On the adaptation of endosteal stem cell niche function in response to stress. Blood 114: 3773-3782, 2009.
48. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446, 2007.
49. Jones D, Glimcher LH, Aliprantis AO. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest 121: 2534-2542, 2011.
50. Karanu FN, Yuefei L, Gallacher L, Sakano S, Bhatia M. Differential response of primitive human CD34- and CD34+ hematopoietic cells to the Notch ligand Jagged-1. Leukemia 17: 1366-1374, 2003.
51. Kassem M, Kveiborg M, Eriksen EF. Production and action of transforming growth factor-beta in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol. Eur J Clin Invest 30: 429-437, 2000.
52. Katoh H, Watabe A, Sugimoto Y, Ichikawa A, Negishi M. Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA transfected Chinese hamster ovary cells. Biochim Biophys Acta 1244: 41-48, 1995.
53. Kelchtermans H, Geboes L, Mitera T, Huskens D, Leclercq G, Matthys P. Activated CD4+CD25+regulatory T cells inhibit osteoclas-togenesis and collagen-induced arthritis. Ann Rheum Dis 68: 744-750, 2009.
54. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121, 2005.
55. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103: 1345-1352, 1999.
56. Kozawa O, Suzuki A, Tokuda H, Uematsu T. Prostaglandin F2a stimulates interleukin-6 synthesis via activation of PKC in osteoblast-like cells. Am J Physiol Endocrinol Metab 272: E208-E211, 1997.
57. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95: 1178-1190, 2005.
58. Lo Celso C, Scadden DT. The haematopoietic stem cell niche at a glance. J Cell Sci 124: 3529-3535, 2011.
59. Lord AM, North TE, Zon LI. Prostaglandin E2: making more of your marrow. Cell Cycle 6: 3054-3057, 2007.
60. Lymperi S, Horwood N, Marley S, Gordon MY, Cope AP, Dazzi F. Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood 111: 1173-1181, 2008.
61. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142: 4047-4054, 2001.
62. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGFbeta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 23: 552-563, 2004.
63. Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE, Aster JC, Bhandoola A, Radtke F, Pear WS. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell 2: 356-366, 2008.
64. Mancini SJ, Mantei N, Dumortier A, Suter U, MacDonald HR, Radtke F. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood 105: 2340-2342, 2005.
65. McKarns SC, Schwartz RH. Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol 174: 2071-2083, 2005.
66. Meng X, Baylink DJ, Sheng M, Wang H, Gridley DS, Lau KH, Zhang XB. Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation. PLoS One 7: e37569, 2012.
67. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, Sartor RB. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 105: 469-478, 2000.
68. Naganawa T, Xiao L, Coffin JD, Doetschman T, Sabbieti MG, Agas D, Hurley MM. Reduced expression and function of bone morphoge-netic protein-2 in bones of Fgf2 null mice. J Cell Biochem 103: 1975-1988, 2008.
69. Nakamura K, Kawaguchi H, Aoyama I, Hanada K, Hiyama Y, Awa T, Tamura M, Kurokawa T. Stimulation of bone formation by intraosseous application of recombinant basic fibroblast growth factor in normal and ovariectomized rabbits. J Orthop Res 15: 307-313, 1997.
70. Nakayama T, Mutsuga N, Tosato G. FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood 109: 1363-1372, 2007.
71. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol 39: 1301-1312, 2009.
72. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108: 25-30, 2001.
73. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 10: 1434-1441, 2001.
74. Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20: 1971-1982, 2012.
75. Nilsson SK, Dooner MS, Weier HU, Frenkel B, Lian JB, Stein GS, Quesenberry PJ. Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice. J Exp Med 189: 729-734, 1999.
76. Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood 97: 2293-2299, 2001.
77. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ, Haylock DN. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106: 1232-1239, 2005.
78. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447: 1007-1011, 2007.
79. Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol 3: 457-484, 2008.
80. Ohishi K, Varnum-Finney B, Bernstein ID. The notch pathway: modulation of cell fate decisions in hematopoiesis. Int J Hematol 75: 449-459, 2002.
81. Onyia JE, Bidwell J, Herring J, Hulman J, Hock JM. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17: 479-484, 1995.
82. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, Slav MM, Nagler A, Lider O, Alon R, Zipori D, Lapidot T. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+)cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95: 3289-3296, 2000.
83. Pelus LM, Broxmeyer HE, Kurland JI, Moore MA. Regulation of macrophage and granulocyte proliferation: specificities of prostaglandin E and lactoferrin. J Exp Med 150: 277-292, 1979.
84. Pelus LM, Broxmeyer HE, Moore MA. Regulation of human myelo-poiesis by prostaglandin E and lactoferrin. Cell Tissue Kinet 14: 515-526, 1981.
85. Pelus LM. Association between colony forming units-granulocyte macrophage expression of Ia-like (HLA-DR) antigen and control of granulocyte and macrophage production. A new role for prostaglandin E. J Clin Invest 70: 568-578, 1982.
86. Pilbeam CC, Harrison JR, Raisz LG. Prostaglandins and bone metabolism. In: Principles of Bone Biology, edited by Bilezikian JP, Raisz LG, and Rodan GA. San Diego, CA: Academic, 1996, p. 715-728.
87. Porter RL, Calvi LM. Communications between bone cells and hematopoietic stem cells. Arch Biochem Biophys 473: 193-200, 2008.
88. Priestley GV, Scott LM, Ulyanova T, Papayannopoulou T. Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood 107: 2959-2967, 2006.
89. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 15: 60-65, 2004.
90. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16: 1787-1794, 2001.
91. Raisz LG, Fall PM. Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: interaction with cortisol. Endocrinology 126: 1654-1659, 1990.
92. Raisz LG, Fall PM, Petersen DN, Lichtler A, Kream BE. Prostaglandin E2 inhibits alpha 1(I)procollagen gene transcription and promoter activity in the immortalized rat osteoblastic clonal cell line Py1a. Mol Endocrinol 7: 17-22, 1993.
93. Rifas L, Arackal S, Weitzmann MN. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem 88: 650-659, 2003.
94. Rixon RH, Whitfield JF. Hypoplasia of the bone marrow in rats following removal of the parathyroid glands. J Cell Physiol 79: 343-352, 1972.
95. Roodman GD. Cell biology of the osteoclast. Exp Hematol 27: 1229-1241, 1999.
96. Rosen CJ, Bilezikian JP. Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86: 957-964, 2001.
97. Rosen V, Wozney JM. Bone morphogenetic proteins. Principles of Bone Biology (2nd ed.), edited by Belizikian J, Raisz LG, and Rodan G. San Diego, CA: Academic, 2002, p. 919-928.
98. Sabbieti MG, Marchetti L, Abreu C, Montero A, Hand AR, Raisz LG, Hurley MM. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology 140: 434-444, 1999.
99. Sabbieti MG, Agas D, Materazzi S, Capacchietti M, Materazzi G, Hurley MM, Menghi G, Marchetti L. Prostaglandin F2alpha involves heparan sulphate sugar chains and FGFRs to modulate osteoblast growth and differentiation. J Cell Physiol 217: 48-59, 2008.
100. Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetschman T, Hurley MM. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol 219: 143-151, 2009.
101. Sabbieti MG, Agas D, Marchetti L, Santoni G, Amantini C, Xiao L, Menghi G, Hurley MM. Signaling pathways implicated in PGF2alpha effects on Fgf2+/+ and Fgf2-/- osteoblasts. J Cell Physiol 224: 465-474, 2010.
102. Sabbieti MG, Agas D, Marchetti L, Coffin JD, Xiao L, Hurley MM. BMP-2 differentially modulates FGF-2 isoform effects in osteoblasts from newborn transgenic mice. Endocrinology 154: 2723-2733, 2013.
103. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673-2682, 2006.
104. Schaniel C, Sirabella D, Qiu J, Niu X, Lemischka IR, Moore KA. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 118: 2420-2429, 2011.
105. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4: 7-25, 1978.
106. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291, 1999.
107. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
108. Siclari VA, Zhu J, Akiyama K, Liu F, Zhang X, Chandra A, Nah HD, Shi S, Qin L. Mesenchymal progenitors residing close to the bone surface are functionally distinct from those in the central bone marrow. Bone 53: 575-586, 2013.
109. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 175: 266-276, 1988.
110. Simsa-Maziel S, Zaretsky J, Reich A, Koren Y, Shahar R, Monsonego-Ornan E. IL-1RI participates in normal growth plate development and bone modeling. Am J Physiol Endocrinol Metab 305: E15-E21, 2013.
111. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52: 1020-1030, 2005.
112. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150: 5321-5329, 1993.
113. Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol 90: 579-586, 2012.
114. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grünewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201: 1781-1791, 2005.
115. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
116. Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, Oida H, Yoshida N, Tanaka T, Katsuyama M, Hasumoto K, Murata T, Hirata M, Ushikubi F, Negishi M, Ichikawa A, Narumiya S. Failure of parturition in mice lacking the prostaglandin F receptor. Science 277: 681-683, 1997.
117. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 282: 11613-11617, 2007.
118. Taichman RS, Emerson SG. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 179: 1677-1682, 1994.
119. Taichman RS, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 87: 518-524, 1996.
120. Taichman RS, Reilly MJ, Emerson SG. The hematopoietic microen-vironment: osteoblasts and the hematopoietic microenvironment. Hema-tology 4: 421-426, 2000.
121. Takahashi N, Katsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123: 2600-2602, 1988.
122. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling crosstalk between RANKL and IFN-gamma. Nature 408: 600-605, 2000.
123. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304, 2007.
124. Tang EH, Shimizu K, Christen T, Rocha VZ, Shvartz E, Tesme-nitsky Y, Sukhova G, Shi GP, Libby P. Lack of EP4 receptors on bone marrow derived cells enhances inflammation in atherosclerotic lesions. Cardiovasc Res 81: 234-243, 2011.
125. Tashjian AH Jr, Goltzman D. On the interpretation of rat carcinoge-nicity studies for human PTH (1-34) and human PTH (1-84). J Bone Miner Res 23: 803-811, 2008.
126. Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, Gilbert L, Nanes MS, Zayzafoon M, Guldberg R, Lamar DL, Singer MA, Lane TF, Kronenberg HM, Weitzmann MN, Pacifici R. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10: 229-240, 2009.
127. Tetradis S, Pilbeam CC, Liu Y, Herschman HR, Kream BE. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3=,5=-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 138: 3594-3600, 1997.
128. Thomson BM, Bennett J, Dean V, Triffitt J, Meikle MC, Loveridge N. Preliminary characterization of porcine bone marrow stromal cells: skeletogenic potential, colony-forming activity, and response to dexa-methasone, transforming growth factor beta, and basic fibroblast growth factor. J Bone Miner Res 8: 1173-1183, 1993.
129. Tokuda H, Kozawa O, Uematsu T. Interleukin (IL)-17 enhances prostaglandin F(2 alpha)-stimulated IL-6 synthesis in osteoblasts. PLEFA 66: 427-433, 2002.
130. Urade Y, Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm 58: 89-120, 2000.
131. Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S, Pear WS, Bernstein ID. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 6: 1278-1281, 2000.
132. Varnum-Finney B, Brashem-Stein C, Bernstein ID. Combined effects of Notch signalling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood 101: 1784-1789, 2003.
133. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103: 3258-3264, 2004.
134. Wang JS. Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Acta Orthop Scand 269: 1-33, 1996.
135. Watanabe A, Yoneyama S, Nakajima M, Sato N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K, Shimoi A, Yamatoya H, Yoshida K, Kohira T. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1- 34)). J Toxicol Sci 37: 617-629, 2012.
136. Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA; RADIUS Investigators. Real-world effectiveness of select biologic and DMARD mono-therapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 22: 185-198, 2006.
137. Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone 39: 485-493, 2006.
138. Weir EC, Lowik CW, Paliwal I, Insogna KL. Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormonere-lated protein. J Bone Miner Res 11: 1474-1481, 1996.
139. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 208: 154-168, 2005.
140. Whitfield JF. Taming psoriatic keratinocytes-PTHs' uses go up another notch. J Cell Biochem 93: 251-256, 2004.
141. Whitfield JF. Parathyroid hormone and leptin-new peptides, expanding clinical prospects. Expert Opin Investig Drugs 14: 251-264, 2005.
142. Whitfield JF. Parathyroid hormone: a novel tool for treating bone marrow depletion in cancer patients caused by chemotherapeutic drugs and ionizing radiation. Cancer Lett 244: 8-15, 2006.
143. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton IJ, van Rooijen N, Alexander KA, Raggatt LJ, Lévesque JP. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116: 4815-4828, 2010.
144. Xie Y, Yin T, Wiegraebe W, He XC, Miller D, Stark D, Perko K, Alexander R, Schwartz J, Grindley JC, Park J, Haug JS, Wunder-lich JP, Li H, Zhang S, Johnson T, Feldman RA, Li L. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457, 97-101, 2009.
145. Xue Y, Xiao Y, Liu J, Karaplis AC, Pollak MR, Brown EM, Miao D, Goltzman D. The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab 302: E841-E851, 2012.
146. Yamaguchi A. Regulation of differentiation pathway of skeletal mesen-chymal cells in cell lines by transforming growth factor-beta superfamily. Semin Cell Biol 6: 165-173, 1995.
147. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 15: 633-640, 2009.
148. Young N, Mikhalkevich N, Yan Y, Chen D, Zheng WP. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. J Immunol 175: 8287-8295, 2005.
149. Yuhki K, Ueno A, Naraba H, Kojima F, Ushikubi F, Narumiya S, Oh-ishi S. Prostaglandin receptors EP2, EP3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy. J Pharmacol Exp Ther 311: 1218-1224, 2004.
150. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425: 836-841, 2003.
151. Zhao M, Ross JT, Itkin T, Perry JM, Venkatraman A, Haug JS, Hembree MJ, Deng CX, Lapidot T, He XC, Li L. FGF signaling facilitates postinjury recovery of mouse hematopoietic system. Blood 120: 1831-1842, 2012.
152. Zhu J, Emerson SG. A new bone to pick: osteoblasts and the haematopoietic stem-cell niche. Bioessays 26: 595-599, 2004.